NCT06810050: An ongoing trial by CAGE Bio Inc.
This trial is ongoing. It must report results 8 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06810050 |
|---|---|
| Title | Safety and Effectiveness of CGB-500 Topical Ointment with 0.5% and 1% Tofacitinib for the Treatment of Atopic Dermatitis: a Randomized, Dose-Ranging, Vehicle-Controlled, Double-Blind Trial |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 18, 2024 |
| Completion date | Aug. 30, 2025 |
| Required reporting date | Aug. 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |